Free

$1 Million IPF Challenge Finalist Pitch & Award

Event Information

Share this event

Date and Time

Location

Location

MATTER

222 Merchandise Mart Plaza

Suite 1230

Chicago, IL 60654

View Map

Event description

Description

Last spring our partners at Three Lakes Partners, along with MATTER, Common Pool and IDEO, harkened innovators from around the world for an ambitious challenge. Design meaningful solutions to improve the quality of life of those suffering from Idiopathic Pulmonary Fibrosis (IPF), an incurable, progressive, and terminal disease of the lungs that is usually fatal within 5-7 years, and kills as many people as breast cancer every year.

The $1 Million IPF Catalyst Challenge is one of the largest healthcare competitions in the United States. With hundreds of registrants and more than 80 final submissions across all types of technology including analytics, engagement, education, monitoring, coordination, and more, the response has been nothing short of extraordinary.

On January 24, join us for the last stage of the IPF Catalyst Challenge, when the nine finalists will have the opportunity to pitch their ideas to our Selection Committee before they decide who the winners of the $1 million purse will be.

Catalyst Challenge Finalists

Team Lead & Primary Organization: Dr. Joseph Jacob, Mayo Clinic Rochester
Proposed Solution: Use computer algorithms to detect early lung fibrosis on CT scans across two newly created, imaging databases.

Team Lead & Primary Organization: Billy Boyle, Owlstone Medical
Proposed Solution: A system used to capture breath samples and test for the presence of trace chemicals related to disease activity, for the early detection of IPF.

Team Lead & Primary Organization: Dr. Robert Hyzy, American Thoracic Society
Proposed Solution: Develop evidence-based quality measures to ensure IPF patients always receive state-of-the-art care to optimize health outcomes.

Team Lead & Primary Organization: Jeremy Walsh, Cambridge Respiratory Innovations Limited
Proposed Solution: A personal respiratory monitor that will provide advance warning of IPF exacerbations, allowing for timely medical intervention.

Team Lead & Primary Organization: Sam Glassenberg, Level Ex, Inc.
Proposed Solution: Educate the global physician community about IPF by using lifelike, virtual patients in a mobile video game to improve clinical decision-making at the point of care.

Team Lead & Primary Organization: Mary Strek, University of Chicago Interstitial Lung Disease (ILD) Team
Proposed Solution: Create accurate, compassionate and unbiased education for IPF patients, caregivers and physicians via a series of comprehensive, web-based educational modules.

Team Lead & Primary Organization: Valerie Obenchain, Advanced Interactive Response Systems, LLC
Proposed Solution: Produce high-quality, portable oxygen safety and monitoring products that improve IPF patient health and caregiver performance.

Team Lead & Primary Organization: Eamonn Costello, patientMpower
Proposed Solution: Give patients the power to live better with IPF through new insights and connections with peers and caregivers through a mobile platform to track their disease using integrated monitors.

Team Lead & Primary Organization: Lesley Hill, Dolby Vivisol
Proposed Solution: Develop a new IPF liquid oxygen (LOX) flask that will provide pulsed and continuous flow oxygen across the range required by IPF patients to maximize the efficiency of the system and the time available away from the reservoir with a single fill.

Event Agenda

5:00pm: Check-in and networking
5:30pm: Program
7:30pm: IPF Catalyst Challenge winners announced
7:45pm: Reception

Together, let’s breathe new life into IPF.

About IPF

IPF is a debilitating disease wherein small fibers scar the patient’s lungs to the point of incapacity. The term idiopathic means the origin is unknown, which makes this disease all the more frustrating for clinicians, researchers, patients, and caregivers alike.

The symptoms, however, are well-documented: the brain and other organs do not get the oxygen they need to function, leading to slower movement, sapped strength, and, eventually, death. Most IPF deaths are caused by respiratory failure, followed by pulmonary hypertension, heart failure, pulmonary embolism, pneumonia, and lung cancer.

The Market

The majority of the 140,000 American IPF patients are diagnosed between 50-75 years old and the average time between first symptoms and diagnosis is over 18 months. Sadly, the majority of IPF patients survive only 3-5 years post-diagnosis.

Lack of awareness leads to a high rate of misdiagnosis, as does the fact that most IPF symptoms also appear in other disease states. There are only two FDA-approved drugs for symptom management, and the only way to truly help patients breathe long-term is through a lung transplant. There is no known cure for IPF.


Share with friends

Date and Time

Location

MATTER

222 Merchandise Mart Plaza

Suite 1230

Chicago, IL 60654

View Map

Save This Event

Event Saved